Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1868 1
1885 1
1887 3
1936 1
1937 1
1947 1
1948 2
1949 2
1950 6
1951 3
1952 6
1953 3
1954 6
1955 5
1956 4
1957 4
1958 4
1959 8
1960 3
1961 5
1962 1
1963 8
1964 15
1965 17
1966 17
1967 33
1968 26
1969 33
1970 30
1971 21
1972 26
1973 17
1974 21
1975 53
1976 75
1977 60
1978 61
1979 75
1980 70
1981 84
1982 75
1983 91
1984 83
1985 129
1986 116
1987 128
1988 134
1989 187
1990 156
1991 217
1992 239
1993 200
1994 218
1995 273
1996 263
1997 262
1998 286
1999 289
2000 241
2001 280
2002 325
2003 291
2004 304
2005 351
2006 385
2007 341
2008 346
2009 363
2010 412
2011 457
2012 547
2013 593
2014 601
2015 637
2016 667
2017 685
2018 756
2019 867
2020 971
2021 1006
2022 1077
2023 1042
2024 1214
2025 1445
2026 620

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19,149 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Freitas-Cortina
Page 1
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2021.
American Diabetes Association. American Diabetes Association. Diabetes Care. 2021 Jan;44(Suppl 1):S15-S33. doi: 10.2337/dc21-S002. Diabetes Care. 2021. PMID: 33298413 Review.
The American Diabetes Association (ADA) "Standards of Medical Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate qua …
The American Diabetes Association (ADA) "Standards of Medical Care in Diabetes" includes the ADA's current clinical practice r …
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2018.
American Diabetes Association. American Diabetes Association. Diabetes Care. 2018 Jan;41(Suppl 1):S13-S27. doi: 10.2337/dc18-S002. Diabetes Care. 2018. PMID: 29222373 Review.
The American Diabetes Association (ADA) "Standards of Medical Care in Diabetes" includes ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality …
The American Diabetes Association (ADA) "Standards of Medical Care in Diabetes" includes ADA's current clinical practice recom …
Review of Treatment for Adenosine Deaminase Deficiency (ADA) Severe Combined Immunodeficiency (SCID).
Secord E, Hartog NL. Secord E, et al. Ther Clin Risk Manag. 2022 Sep 22;18:939-944. doi: 10.2147/TCRM.S350762. eCollection 2022. Ther Clin Risk Manag. 2022. PMID: 36172599 Free PMC article. Review.
The most complete form of ADA leads to severe combined immune deficiency (SCID). Treatment with enzyme replacement therapy (ERT) was developed in the 1970s and became the treatment for ADA SCID by the 1980s. ...This review covers the history of ADA SCID, the …
The most complete form of ADA leads to severe combined immune deficiency (SCID). Treatment with enzyme replacement therapy (ERT) was …
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2019.
American Diabetes Association. American Diabetes Association. Diabetes Care. 2019 Jan;42(Suppl 1):S13-S28. doi: 10.2337/dc19-S002. Diabetes Care. 2019. PMID: 30559228 Review.
The American Diabetes Association (ADA) "Standards of Medical Care in Diabetes" includes ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality …
The American Diabetes Association (ADA) "Standards of Medical Care in Diabetes" includes ADA's current clinical practice recom …
Tirzepatide Immunogenicity on Pharmacokinetics, Efficacy, and Safety: Analysis of Data From Phase 3 Studies.
Mullins GR, Hodsdon ME, Li YG, Anglin G, Urva S, Schneck K, Bardos JN, Martins RF, Brown K, Calderon B. Mullins GR, et al. J Clin Endocrinol Metab. 2024 Jan 18;109(2):361-369. doi: 10.1210/clinem/dgad532. J Clin Endocrinol Metab. 2024. PMID: 37700637 Free PMC article.
Samples for ADA characterization were collected at SURPASS trial sites. Participants included ADA-evaluable TZP-treated patients with type 2 diabetes (N = 5025). ...More TE ADA+ patients experienced hypersensitivity reactions or injection site reactions than …
Samples for ADA characterization were collected at SURPASS trial sites. Participants included ADA-evaluable TZP-treated patien …
Immunogenicity of TNF-Inhibitors.
Atiqi S, Hooijberg F, Loeff FC, Rispens T, Wolbink GJ. Atiqi S, et al. Front Immunol. 2020 Feb 26;11:312. doi: 10.3389/fimmu.2020.00312. eCollection 2020. Front Immunol. 2020. PMID: 32174918 Free PMC article. Review.
Retrospectively, we recognize this has led to an underestimation of the amount of ADA produced due to drug interference. Drug-tolerant ADA assays also detect ADA in the presence of drug, which has contributed to the currently reported higher incidence of A …
Retrospectively, we recognize this has led to an underestimation of the amount of ADA produced due to drug interference. Drug-toleran …
A new andrographolide derivative ADA targeting SIRT3-FOXO3a signaling mitigates cognitive impairment by activating mitophagy and inhibiting neuroinflammation in Apoe4 mice.
Zhou Y, Zhao Q, Zhang Y, Di L, Xue F, Xu W, Gao W, Guo Y, He Y, Kou J, Qin Y, Xie X, Du L, Han G, Pang X. Zhou Y, et al. Phytomedicine. 2024 Feb;124:155298. doi: 10.1016/j.phymed.2023.155298. Epub 2023 Dec 17. Phytomedicine. 2024. PMID: 38185066
Inhibited SIRT3 and FOXO3a in Apoe4 mice brains were elevated after ADA treatment. ADA also lightened the neuroinflammation caused by NLRP3 inflammasome activation. ...CONCLUSION: ADA exerted stronger cognition-enhancing ability in relative to AGA, and ADA …
Inhibited SIRT3 and FOXO3a in Apoe4 mice brains were elevated after ADA treatment. ADA also lightened the neuroinflammation ca …
Adenosine Deaminase Deficiency.
Hershfield M, Tarrant T. Hershfield M, et al. 2006 Oct 3 [updated 2025 Dec 4]. In: Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2026. 2006 Oct 3 [updated 2025 Dec 4]. In: Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2026. PMID: 20301656 Free Books & Documents. Review.
However, ADA-CID is identified by TMS NBS since the ADA substrates Ado and dAdo are increased. ...An individual who inherits two pathogenic ADA variants will have either ADA-SCID or a delayed or late-onset ADA-CID phenotype that correlates with …
However, ADA-CID is identified by TMS NBS since the ADA substrates Ado and dAdo are increased. ...An individual who inherits t …
Antidrug antibodies to adalimumab do not associate with immunologically related adverse events.
Tourdot S, Vazquez-Abad MD, Cox DS, Cai CH, Wang K, Zhang W, Lepsy C. Tourdot S, et al. Front Immunol. 2025 Feb 27;15:1457993. doi: 10.3389/fimmu.2024.1457993. eCollection 2024. Front Immunol. 2025. PMID: 40084239 Free PMC article. Clinical Trial.
ADA/NAb titers stabilized by week 16 without boosters. C(trough) was lower in patients with ADA-positive than ADA-negative samples throughout the study. From weeks 30-32, AUC(tau), C(max), and C(av) were lower in ADA-positive than ADA-negative s …
ADA/NAb titers stabilized by week 16 without boosters. C(trough) was lower in patients with ADA-positive than ADA-negat …
Model-Informed Immunogenicity Assessment of Nivolumab as Monotherapy and in Combination with Ipilimumab.
Zhao Y, Li L, Ma J, Roy A, Bello A, Sheng J, Hamuro L. Zhao Y, et al. AAPS J. 2025 Apr 25;27(4):79. doi: 10.1208/s12248-025-01069-y. AAPS J. 2025. PMID: 40281256
Despite the occurrence of nivolumab ADA being associated with lower nivolumab exposures, objective response rates (ORR) were similar in ADA-positive and negative patients, and ADA titer was not a significant predictor of response. ...This model-based approach …
Despite the occurrence of nivolumab ADA being associated with lower nivolumab exposures, objective response rates (ORR) were similar …
19,149 results
You have reached the last available page of results. Please see the User Guide for more information.